Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts

PRINCETON, N.J., Feb. 17 /PRNewswire-FirstCall/ — Novo Nordisk, a global healthcare company focusing on diabetes care, today announced the appointment of Andy Ajello as vice president for National Diabetes Sales, Managed Care and Government Accounts. Ajello joins the Executive Team and will report directly to Jerzy Gruhn, president of Novo Nordisk’s North American affiliate.

Ajello was most recently the associate vice president of Diabetes Sales for the eastern area, where he led more than 600. In his new position, he will lead the company’s 2,000-person field sales organization. Ajello joined Novo Nordisk in 2001 where he helped to launch NovoLog(R) (insulin aspart [rDNA origin] injection).

“In his eight years at Novo Nordisk, Andy has developed an impressive track record for building high performing field sales teams,” said Jerzy Gruhn, president of Novo Nordisk Inc. “His focus on cross-functional collaboration, quick decision-making and strategic execution will help us continue our growth and ultimately realize our ambition of changing diabetes.”

Ajello has been recognized and awarded at Novo Nordisk for achievements in sales leadership, training, and marketing, including being named as the Novo Nordisk International Sales Manager of the Year in 2007. Ajello’s unique style and insights into team development and management were featured in a Wall Street Journal article in 2008. Prior to Novo Nordisk, Ajello held a 10-year tenure at GlaxoSmithKline.

Ajello received a Bachelor’s degree in economics from Susquehanna University.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.

SOURCE Novo Nordisk